|
|
|
|
|
|
Sponsored by: |
Organon |
Information provided by: | Organon |
ClinicalTrials.gov Identifier: | NCT00750919 |
This trial is a twenty-six week, open label extension trial to investigate safety and explore efficacy of org 50081in patients with insomnia who completed protocol 21106.
Condition | Intervention | Phase |
Sleep Initiation and Maintenance Disorders Mental Disorders Dyssomnias Sleep Disorders Sleep Disorders, Intrinsic |
Drug: Org 50081 |
Phase III |
MedlinePlus related topics: | Mental Health Sleep Disorders |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Twenty-Six Weeks, Open-Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 21106 |
Estimated Enrollment: | 211 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Arm 1: Experimental
Org 50081 one tablet daily
|
Drug: Org 50081
4.5 mg tablet / once daily
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | NV Organon, part of Schering-Plough Corporation ( Study Director ) |
Study ID Numbers: | 176003 |
First Received: | September 10, 2008 |
Last Updated: | September 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00750919 |
Health Authority: | United States: Food and Drug Administration |
|
|
|